The main purpose of this legislation, known as the "No Handouts for Drug Advertisements Act," is to prevent pharmaceutical companies from deducting the costs of advertising certain drugs from their taxable income. This aims to reduce the financial incentives for companies to engage in extensive direct-to-consumer advertising, which can contribute to rising drug prices and potentially mislead consumers about the benefits and risks of medications.